TU
JAZZ icon

TDAM USA’s Jazz Pharmaceuticals JAZZ Stock Holding History

TDAM USA’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-2,818
Closed -$486K – 332
2018
Q2 		$486K Buy
2,818
+363
+15% +$59.3K 0.03% 256
2018
Q1 		$371K Sell
2,455
-518
-17% -$76K 0.02% 271
2017
Q4 		$400K Sell
2,973
-1,906
-39% -$264K 0.02% 266
2017
Q3 		$714K Buy
4,879
+534
+12% +$80.8K 0.04% 232
2017
Q2 		$676K Sell
4,345
-494
-10% -$75.5K 0.03% 246
2017
Q1 		$702K Sell
4,839
-380
-7% -$49.5K 0.04% 243
2016
Q4 		$569K Buy
5,219
+1,369
+36% +$152K 0.03% 269
2016
Q3 		$468K Buy
+3,850
New +$519K 0.02% 296
2014
Q3 		– Sell
-1,559
Closed -$229K – 332
2014
Q2 		$229K Buy
1,559
+45
+3% +$6.24K 0.01% 299
2014
Q1 		$210K Buy
+1,514
New +$228K 0.01% 307

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

TDAM USA's JAZZ Position: Q3 2018 in Review

TDAM USA sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2018, closing a stake of 2,818 shares — an estimated $486K sold.

TDAM USA first reported a position in JAZZ in Q1 2014 and held it in 10 quarters. The position peaked at $714K in Q3 2017. 403 funds tracked by Wall St. Rank hold JAZZ as of Q3 2018.

  • TDAM USA reported no remaining Jazz Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • TDAM USA sold 2,818 Jazz Pharmaceuticals shares in Q3 2018, an estimated $486K.
  • TDAM USA first reported a position in Jazz Pharmaceuticals in Q1 2014 and held it in 10 quarters.
  • TDAM USA's Jazz Pharmaceuticals position peaked at $714K in Q3 2017.
  • 403 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2018.

Based on TDAM USA's 13F filing for Q3 2018, filed 1 Nov 2018.